TY - JOUR AU - Jemal, A. AU - Bray, F. AU - Center, M. M. AU - Ferlay, J. AU - Ward, E. AU - Forman, D. PY - 2011 DA - 2011// TI - Global cancer statistics JO - CA Cancer J Clin VL - 61 UR - https://doi.org/10.3322/caac.20107 DO - 10.3322/caac.20107 ID - Jemal2011 ER - TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Ward, E. AU - Hao, Y. AU - Xu, J. AU - Thun, M. J. PY - 2009 DA - 2009// TI - Cancer statistics, 2009 JO - CA Cancer J Clin VL - 59 UR - https://doi.org/10.3322/caac.20006 DO - 10.3322/caac.20006 ID - Jemal2009 ER - TY - JOUR AU - Billmeier, S. E. AU - Ayanian, J. Z. AU - Zaslavsky, A. M. AU - Nerenz, D. R. AU - Jaklitsch, M. T. AU - Rogers, S. O. PY - 2011 DA - 2011// TI - Predictors and Outcomes of Limited Resection for Early-Stage Non–Small Cell Lung Cancer JO - J Natl Cancer Inst VL - 103 UR - https://doi.org/10.1093/jnci/djr387 DO - 10.1093/jnci/djr387 ID - Billmeier2011 ER - TY - JOUR AU - Holdenrieder, S. AU - Pawel, J. AU - Dankelmann, E. AU - Duell, T. AU - Faderl, B. AU - Markus, A. PY - 2008 DA - 2008// TI - Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung Cancer JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0678 DO - 10.1158/1078-0432.CCR-08-0678 ID - Holdenrieder2008 ER - TY - JOUR AU - Schneider, J. AU - Philipp, M. AU - Velcovsky, H. G. AU - Morr, H. AU - Katz, N. PY - 2003 DA - 2003// TI - Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases JO - Anticancer Res VL - 23 ID - Schneider2003 ER - TY - JOUR AU - Lee, J. H. AU - Chang, J. H. PY - 2005 DA - 2005// TI - Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer JO - Chest VL - 128 UR - https://doi.org/10.1378/chest.128.4.2298 DO - 10.1378/chest.128.4.2298 ID - Lee2005 ER - TY - JOUR AU - Xiao, M. AU - Jia, S. AU - Wang, H. AU - Wang, J. AU - Huang, Y. AU - Li, Z. PY - 2013 DA - 2013// TI - Overexpression of LAPTM4B: an independent prognostic marker in breast cancer JO - J Cancer Res Clin Oncol VL - 139 UR - https://doi.org/10.1007/s00432-012-1368-y DO - 10.1007/s00432-012-1368-y ID - Xiao2013 ER - TY - JOUR AU - Zhou, L. AU - He, X. D. AU - Yu, J. C. AU - Zhou, R. L. AU - Shan, Y. AU - Rui, J. A. PY - 2011 DA - 2011// TI - Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells JO - Surgery VL - 150 UR - https://doi.org/10.1016/j.surg.2010.12.010 DO - 10.1016/j.surg.2010.12.010 ID - Zhou2011 ER - TY - JOUR AU - Zhou, L. AU - He, X. D. AU - Chen, J. AU - Cui, Q. C. AU - Qu, Q. AU - Rui, J. A. PY - 2007 DA - 2007// TI - Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and postresectional survival of gallbladder carcinoma JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2006.10.025 DO - 10.1016/j.ejca.2006.10.025 ID - Zhou2007 ER - TY - JOUR AU - Yin, M. Z. AU - Li, C. AU - Li, X. AU - Lou, G. AU - Miao, B. AU - Liu, X. PY - 2011 DA - 2011// TI - Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer JO - J Surg Oncol VL - 104 UR - https://doi.org/10.1002/jso.21912 DO - 10.1002/jso.21912 ID - Yin2011 ER - TY - JOUR AU - Yang, H. AU - Lin, M. AU - Xiong, F. X. AU - Yang, Y. AU - Nie, X. AU - McNutt, M. A. PY - 2011 DA - 2011// TI - Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients JO - Surg Today VL - 41 UR - https://doi.org/10.1007/s00595-010-4338-5 DO - 10.1007/s00595-010-4338-5 ID - Yang2011 ER - TY - JOUR AU - Yang, H. AU - Xiong, F. X. AU - Qi, R. AU - Liu, Z. AU - Lin, M. AU - Rui, J. PY - 2010 DA - 2010// TI - LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma JO - J Surg Oncol VL - 101 UR - https://doi.org/10.1002/jso.21489 DO - 10.1002/jso.21489 ID - Yang2010 ER - TY - JOUR AU - Peng, C. AU - Zhou, R. L. AU - Shao, G. Z. AU - Rui, J. A. AU - Wang, S. B. AU - Lin, M. PY - 2005 DA - 2005// TI - Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma JO - World J Gastroenterol VL - 11 UR - https://doi.org/10.3748/wjg.v11.i18.2704 DO - 10.3748/wjg.v11.i18.2704 ID - Peng2005 ER - TY - JOUR AU - Zhang, H. AU - Tian, B. AU - Yu, H. AU - Yao, H. AU - Gao, Z. PY - 2014 DA - 2014// TI - LAPTM4B-35 protein as a potential therapeutic target in gastric cancer JO - Tumour Biol VL - 35 UR - https://doi.org/10.1007/s13277-014-2599-0 DO - 10.1007/s13277-014-2599-0 ID - Zhang2014 ER - TY - JOUR AU - Meng, F. AU - Luo, C. AU - Hu, Y. AU - Yin, M. AU - Lin, M. AU - Lou, G. PY - 2010 DA - 2010// TI - Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study JO - Int J Gynecol Pathol VL - 29 UR - https://doi.org/10.1097/PGP.0b013e3181e0898e DO - 10.1097/PGP.0b013e3181e0898e ID - Meng2010 ER - TY - JOUR AU - Meng, Y. AU - Wang, L. AU - Chen, D. AU - Chang, Y. AU - Zhang, M. AU - XU, J. -. J. PY - 2016 DA - 2016// TI - LAPTM4B: an oncogene in various solid tumors and its functions JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2016.189 DO - 10.1038/onc.2016.189 ID - Meng2016 ER - TY - JOUR AU - Maki, Y. AU - Fujimoto, J. AU - Lang, W. AU - Xu, L. AU - Behrens, C. AU - Wistuba, I. I. PY - 2015 DA - 2015// TI - LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep13846 DO - 10.1038/srep13846 ID - Maki2015 ER - TY - JOUR AU - Kong, F. AU - Gao, F. AU - Chen, J. AU - Sun, Y. AU - Zhang, Y. AU - Liu, H. PY - 2016 DA - 2016// TI - Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer JO - Oncotarget VL - 7 ID - Kong2016 ER - TY - JOUR AU - Wang, L. AU - Meng, Y. AU - Xu, J. J. AU - Zhang, Q. Y. PY - 2018 DA - 2018// TI - The transcription factor AP4 promotes oncogenic phenotypes and cisplatin resistance by regulating LAPTM4B expression JO - Mol Cancer Res VL - 16 UR - https://doi.org/10.1158/1541-7786.MCR-17-0519 DO - 10.1158/1541-7786.MCR-17-0519 ID - Wang2018 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Okabe, T. AU - Okamoto, I. AU - Tamura, K. AU - Terashima, M. AU - Yoshida, T. AU - Satoh, T. PY - 2007 DA - 2007// TI - Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3339 DO - 10.1158/0008-5472.CAN-06-3339 ID - Okabe2007 ER - TY - JOUR AU - Segovia-Mendoza, M. AU - González-González, M. E. AU - Barrera, D. AU - Díaz, L. AU - García-Becerra, R. PY - 2015 DA - 2015// TI - Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence JO - Am J Cancer Res VL - 5 ID - Segovia-Mendoza2015 ER - TY - JOUR AU - Segovia-Mendoza, M. AU - Díaz, L. AU - González-González, M. E. AU - Martínez- Reza, I. AU - García-Quiroz, J. AU - Prado-Garcia, H. AU - Ibarra-Sánchez, M. J. AU - Esparza-López, J. AU - Larrea, F. AU - García-Becerra, R. PY - 2015 DA - 2015// TI - Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells JO - J Steroid Biochem Mol Biol VL - 148 UR - https://doi.org/10.1016/j.jsbmb.2014.12.006 DO - 10.1016/j.jsbmb.2014.12.006 ID - Segovia-Mendoza2015 ER - TY - JOUR AU - Wang, J. AU - Wang, B. AU - Chu, H. AU - Yao, Y. PY - 2016 DA - 2016// TI - Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations JO - Onco Targets Ther VL - 9 UR - https://doi.org/10.2147/OTT.S106399 DO - 10.2147/OTT.S106399 ID - Wang2016 ER - TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Yang, H. AU - Xiong, F. AU - Wei, X. AU - Yang, Y. AU - McNutt, M. A. AU - Zhou, R. PY - 2010 DA - 2010// TI - Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo JO - Cancer Lett VL - 294 UR - https://doi.org/10.1016/j.canlet.2010.02.006 DO - 10.1016/j.canlet.2010.02.006 ID - Yang2010 ER - TY - JOUR AU - Yin, M. AU - Lou, C. AU - Zhang, W. AU - Meng, F. AU - Zhang, H. AU - Ning, X. PY - 2012 DA - 2012// TI - LAPTM4B overexpression is an novel independent prognostic marker for metastatic ovarian tumors JO - Int J Gynecol Cancer VL - 22 UR - https://doi.org/10.1097/IGC.0b013e318234f9ac DO - 10.1097/IGC.0b013e318234f9ac ID - Yin2012 ER - TY - JOUR AU - Xiao, M. AU - Yang, S. AU - Meng, F. AU - Qin, Y. AU - Yang, Y. AU - Jia, S. PY - 2017 DA - 2017// TI - LAPTM4B predicts axillary lymph node metastasis in breast Cancer and promotes breast Cancer cell aggressiveness in vitro JO - Cell Physiol Biochem VL - 41 UR - https://doi.org/10.1159/000464115 DO - 10.1159/000464115 ID - Xiao2017 ER - TY - JOUR AU - Meng, F. AU - Chen, X. AU - Song, H. AU - Lou, G. PY - 2015 DA - 2015// TI - LAPTM4B down regulation inhibits the proliferation, invasion and angiogenesis of Hela cells in vitro JO - Cell Physiol Biochem VL - 37 UR - https://doi.org/10.1159/000430216 DO - 10.1159/000430216 ID - Meng2015 ER - TY - JOUR AU - Meng, Y. AU - Wang, L. AU - Xu, J. AU - Zhang, Q. PY - 2018 DA - 2018// TI - AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity JO - Mol Oncol VL - 12 UR - https://doi.org/10.1002/1878-0261.12171 DO - 10.1002/1878-0261.12171 ID - Meng2018 ER - TY - JOUR AU - Xue, C. AU - Hu, Z. AU - Jiang, W. AU - Zhao, Y. AU - Xu, F. AU - Huang, Y. PY - 2012 DA - 2012// TI - National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China JO - Lung Cancer VL - 77 UR - https://doi.org/10.1016/j.lungcan.2012.04.014 DO - 10.1016/j.lungcan.2012.04.014 ID - Xue2012 ER - TY - JOUR AU - Mitsudomi, T. AU - Kosaka, T. AU - Endoh, H. AU - Horio, Y. AU - Hida, T. AU - Mori, S. PY - 2005 DA - 2005// TI - Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.00.992 DO - 10.1200/JCO.2005.00.992 ID - Mitsudomi2005 ER - TY - JOUR AU - Takeda, M. AU - Okamoto, I. AU - Fujita, Y. AU - Arao, T. AU - Ito, H. AU - Fukuoka, M. PY - 2010 DA - 2010// TI - De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer JO - J Thorac Oncol VL - 5 UR - https://doi.org/10.1097/JTO.0b013e3181cee47e DO - 10.1097/JTO.0b013e3181cee47e ID - Takeda2010 ER - TY - JOUR AU - Okamura, K. AU - Takayama, K. AU - Izumi, M. AU - Harada, T. AU - Furuyama, K. AU - Nakanishi, Y. PY - 2013 DA - 2013// TI - Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer JO - Lung Cancer VL - 80 UR - https://doi.org/10.1016/j.lungcan.2013.01.002 DO - 10.1016/j.lungcan.2013.01.002 ID - Okamura2013 ER - TY - JOUR AU - Zhang, H. AU - Qi, S. AU - Zhang, T. AU - Wang, A. AU - Liu, R. AU - Guo, J. PY - 2015 DA - 2015// TI - miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression JO - Oncotarget VL - 6 ID - Zhang2015 ER - TY - JOUR AU - Pelengaris, S. AU - Khan, M. AU - Evan, G. I. PY - 2002 DA - 2002// TI - Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression JO - Cell VL - 109 UR - https://doi.org/10.1016/S0092-8674(02)00738-9 DO - 10.1016/S0092-8674(02)00738-9 ID - Pelengaris2002 ER - TY - JOUR AU - Eisenman, R. N. PY - 2001 DA - 2001// TI - Deconstructing myc JO - Genes Dev VL - 15 UR - https://doi.org/10.1101/gad928101 DO - 10.1101/gad928101 ID - Eisenman2001 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Tian, M. AU - Chen, Y. AU - Tian, D. AU - Qiao, X. AU - Ma, Z. AU - Li, J. PY - 2017 DA - 2017// TI - Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells JO - Gene VL - 626 UR - https://doi.org/10.1016/j.gene.2017.05.006 DO - 10.1016/j.gene.2017.05.006 ID - Tian2017 ER - TY - JOUR AU - Tan, X. AU - Thapa, N. AU - Sun, Y. AU - Anderson, R. A. PY - 2015 DA - 2015// TI - A kinase-independent role for EGF receptor in autophagy initiation JO - Cell VL - 160 UR - https://doi.org/10.1016/j.cell.2014.12.006 DO - 10.1016/j.cell.2014.12.006 ID - Tan2015 ER - TY - JOUR AU - Tan, X. AU - Sun, Y. AU - Thapa, N. AU - Liao, Y. AU - Hedman, A. C. AU - Anderson, R. A. PY - 2015 DA - 2015// TI - LAPTM4B is a PtdIns (4,5) P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation JO - EMBO J VL - 34 UR - https://doi.org/10.15252/embj.201489425 DO - 10.15252/embj.201489425 ID - Tan2015 ER - TY - JOUR AU - Cully, M. AU - You, H. AU - Levine, A. J. AU - Mak, T. W. PY - 2006 DA - 2006// TI - Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc1819 DO - 10.1038/nrc1819 ID - Cully2006 ER - TY - JOUR AU - Liu, Q. AU - Li, A. AU - Tian, Y. AU - Wu, J. D. AU - Liu, Y. AU - Li, T. AU - Chen, Y. AU - Han, X. AU - Wu, K. PY - 2016 DA - 2016// TI - The CXCL8-CXCR1/2 pathways in cancer JO - Cytokine Growth Factor Rev VL - 31 UR - https://doi.org/10.1016/j.cytogfr.2016.08.002 DO - 10.1016/j.cytogfr.2016.08.002 ID - Liu2016 ER - TY - JOUR AU - Shibata, T. AU - Kawano, T. AU - Nagayasu, H. AU - Okumura, K. AU - Arisue, M. AU - Hamada, J. PY - 1996 DA - 1996// TI - Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth JO - Tumour Biol VL - 17 UR - https://doi.org/10.1159/000217979 DO - 10.1159/000217979 ID - Shibata1996 ER - TY - JOUR AU - Shepherd, F. A. AU - Rodrigues Pereira, J. AU - Ciuleanu, T. AU - Tan, E. H. AU - Hirsh, V. AU - Thongprasert, S. PY - 2005 DA - 2005// TI - Erlotinib in previously treated non-small-cell lung cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050753 DO - 10.1056/NEJMoa050753 ID - Shepherd2005 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Thongprasert, S. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER -